Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
DANVERS, Mass., April 13, 2017 -- Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, May 4, 2017, the Company will release financial results for the fourth quarter of fiscal 2017. The Company will host a conference call to discuss the results on Thursday, May 4, 2017, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer; Michael Tomsicek, Vice President and Chief Financial Officer, will host the conference call.
To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11 a.m. EDT May 4, 2017 through 11:00 a.m. EDT on May 7, 2017. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 3991529.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
For further information please contact: Ingrid Goldberg Director, Investor Relations 978-646-1590 [email protected]
